In today’s recent session, 0.98 million shares of the Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) have been traded, and its beta is 1.06. Most recently the company’s share price was $0.68, and it changed around $0.02 or 3.05% from the last close, which brings the market valuation of the company to $246.96M. LXRX at last check was trading at a discount to its 52-week high of $2.45, offering almost -260.29% off that amount. The share price’s 52-week low was $0.28, which indicates that the recent value has risen by an impressive 58.82% since then. We note from Lexicon Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 4.53 million shares, with the 3-month average coming to 15.16 million.
Lexicon Pharmaceuticals Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.00. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 2 recommended LXRX as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Lexicon Pharmaceuticals Inc is expected to report earnings per share of -0.08 for the current quarter.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) trade information
Instantly LXRX has been showing a green trend so far today with a performance of 3.05% on intraday trading today. The performance over the last five days has remained in the green territory. The company’s shares are currently down -7.92% year-to-date, but still up 22.35% over the last five days. On the other hand, Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) is -4.01% down in the 30-day period. We can see from the shorts that 37.27 million shares have been sold at a short interest cover period of 2.91 day(s).
The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to increase their stock price by 88.67% from its current value. Analyst projections state that LXRX is forecast to be at a low of $6 and a high of $6.
Lexicon Pharmaceuticals Inc (LXRX) estimates and forecasts
The year-over-year growth rate is expected to be -55.50%, down from the previous year.
Consensus estimates provided by 4 financial analysts predict the company will bring in an average of 4.87M in revenue for the current quarter. 4 analysts expect Lexicon Pharmaceuticals Inc to make 4.92M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 1.65M and 1.75M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 195.54%. Forecasts for the next quarter put sales growth at 181.14%.
Lexicon Pharmaceuticals Inc earnings are expected to increase by 49.60% in 2025, but the outlook is positive 30.30% per year for the next five years.
LXRX Dividends
Lexicon Pharmaceuticals Inc’s next quarterly earnings report is expected to be released on 2025-May-12.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.15% of Lexicon Pharmaceuticals Inc shares, and 74.93% of them are in the hands of institutional investors. The stock currently has a share float of 75.80%. Lexicon Pharmaceuticals Inc stock is held by 165.0 institutions, with ARTAL GROUP S.A. being the largest institutional investor. By 2024-06-30, it held 56.3318% of the shares, which is about 175.1 million shares worth $294.17 million.
FMR LLC, with 12.4462% or 38.69 million shares worth $64.99 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Mar 31, 2025 . The former held 10.16 shares worth $6.86 million, making up 2.80% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 5.15 shares worth around $3.47 million, which represents about 1.42% of the total shares outstanding.
